Development PipelineSGN-PDL1V

a novel, investigational antibody–drug conjugate directed to PD-L1

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNPDL1V-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-PDL1V and ongoing clinical trials

Detailed information about SGN-PDL1V clinical trials